Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update : This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF).
Adverse effects
Bone density
Glucocorticoids
Guideline
Osteoporosis
Prednisone
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
17
08
2022
accepted:
16
09
2022
pubmed:
9
11
2022
medline:
23
11
2022
entrez:
8
11
2022
Statut:
ppublish
Résumé
Guidelines and recommendations developed and endorsed by the International Osteoporosis Foundation (IOF) are intended to provide guidance for particular pattern of practice for physicians who usually prescribe glucocorticoid (GC) therapy, and not to dictate the care of a particular patient. Adherence to the recommendations within this guideline is voluntary and the ultimate determination regarding their application should be made by the physician in light of each patient's circumstances. Guidelines and recommendations are intended to promote a desirable outcome but cannot guarantee any specific outcome. This guideline and its recommendations are not intended to dictate payment, reimbursement or insurance decisions. Guidelines and recommendations are subjected to periodic revisions as a consequence of the evolution of medicine, technology and clinical practice. A panel of Latin American (LATAM) experts specialized in osteoporosis with recognized clinical experience in managing patients with glucocorticoid-induced osteoporosis (GIO) met to produce evidence-based LATAM recommendations for the diagnosis and management of GIO. These guidelines are particularly intended to general practitioners and primary care physicians who prescribe GC treatments in LATAM to guide their daily clinical practice in terms of evaluation, prevention and treatment of GIO. These recommendations were based on systematic literature review using MEDLINE, EMBASE, SCOPUS and COCHRANE Library database during the period from 2012 to 2021. Randomized clinical trials (RCT), systematic reviews of RCT, controlled observational studies, guidelines and consensus were considered. Based on the review and expert opinion the panel members voted recommendations during two successive rounds of voting by panel members. Agreements for each statement were considered if a concordance of at least 70% was achieved following Delphi methodology. Grading of recommendations was made according to the Oxford Centre for the Evidence-based Medicine (EBM) criteria. Among five GIO guidelines and consensus initially identified, two of them (American College of Rheumatology 2017 and the Brazilian Guidelines 2021) were selected for comparison considering the latter as the most current guides in the LATAM region. Based on this methodology fifty statements were issued. All of them but four (1.20, 1.21, 1.23 and 4.2) attained agreement.
Identifiants
pubmed: 36348222
doi: 10.1007/s40520-022-02261-2
pii: 10.1007/s40520-022-02261-2
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2591-2602Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Walsh LJ, Wong CA, Pringle M et al (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344–346
pubmed: 8760745
pmcid: 2351752
doi: 10.1136/bmj.313.7053.344
Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000
pubmed: 10841167
doi: 10.1359/jbmr.2000.15.6.993
Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787
pubmed: 12378366
doi: 10.1007/s001980200108
Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229
pubmed: 14613287
doi: 10.1002/art.11283
Kaji H, Yamauchi M, Chihara K et al (2006) The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 53:27–34
pubmed: 16543669
doi: 10.1507/endocrj.53.27
Buckley L, Guyatt G, Fink HA et al (2017) American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095–1110
doi: 10.1002/acr.23279
Gobierno Federal del Estado de México (2012) Norma oficial mexicana NOM-035-SSA2–2012 para la prevención y control de enfermedades en la perimenopausia y postmenopausia de la mujer. Criterios para brindar atención médica. Secretaria de Salud-Gobierno Federal del Estado de México. SEGOB. Diario oficial de la federación. https://dof.gob.mx/nota_detalle.php?codigo=5284235&fecha=07/01/2013#gsc.tab=0
Messina OD, Somma LF, Tamporenea MI et al (2016) Guías para el diagnóstico, la prevención y el tratamiento de la osteoporosis inducida por glucocorticoides en el adulto. Actual Osteol 12:107–25
Pereira RM, Perez MO, Paula AP et al (2021) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian society of rheumatology (2020). Arch Osteoporosis 16:1–16
doi: 10.1007/s11657-021-00902-z
OCEBM Levels of Evidence Working Group*. “The Oxford Levels of Evidence 2” Oxford Centre for Evidence-Based Medicine. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence * OCEBM Levels of evidence working group = Jeremy Howick, Jain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard and Mary Hodgkinson
Boulkedid R, Abdoul H, Loustau M et al (2011) Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE 6:e20476
pubmed: 21694759
pmcid: 3111406
doi: 10.1371/journal.pone.0020476
Compston J, Cooper A, Cooper C et al (2017) National Osteoporosis Guideline Group (NOGG) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43
pubmed: 28425085
pmcid: 5397452
doi: 10.1007/s11657-017-0324-5
Laurent MR, Goemaere S, Verroken C et al (2022) Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the belgian bone club. Front Endocrinol 13:908727
doi: 10.3389/fendo.2022.908727
Park SY, Gong HS, Kim KM et al (2018) Korean guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Metab 25:195–211
pubmed: 30574464
pmcid: 6288607
doi: 10.11005/jbm.2018.25.4.195
Weare-Regales N, Hudey SN, Lockey RF (2021) Practical guidance for prevention and management of glucocorticoid-induced osteoporosis for the allergist/immunologist. J Allergy Clin Immunol Pract 9:1841–1850
pubmed: 33444813
doi: 10.1016/j.jaip.2020.12.050
Preedy VR, Watson RR (2010) 5-Point Likert Scale. In: Ronald R (ed) Handbook of disease burdens and quality of life measures. Springer, New York
doi: 10.1007/978-0-387-78665-0
Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913
pubmed: 23873876
doi: 10.1136/annrheumdis-2013-203249
Chalitsios C, Shaw D, McKeever TM (2021) Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population—based nested case-control studies. Thorax BMJ 76:21–28
doi: 10.1136/thoraxjnl-2020-215664
Egeberg A, Schwartz P, Harslof T et al (2021) Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. JAMA Dermatol 157:275–282
pubmed: 33471030
doi: 10.1001/jamadermatol.2020.4968
Gonzalez AV, Coulombe J, Ernst P et al (2018) Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest 153:321–328
pubmed: 28716642
doi: 10.1016/j.chest.2017.07.002
Kanis JA, Hans D, Cooper C et al (2011) Task force of the FRAX Initiative Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411
pubmed: 21779818
doi: 10.1007/s00198-011-1713-z
Messina OD, Vidal LF, Vidal M et al (2021) Management of glucocorticoid-induced osteoporosis. Aging Clin Exp Res 33:793–804
pubmed: 33751462
doi: 10.1007/s40520-021-01823-0
Morales Torres JA, Clark PE, Deleze-Hinojosa M et al (2010) Fracture risk assessment in Latin america: is FRAX an adaptable instrument for the region? Clin Rheumatol 29:1085–1091
pubmed: 20632196
doi: 10.1007/s10067-010-1489-0
Clark PE, Denova Gutierrez E, Zerbini C et al (2018) FRAX-based intervention and assessment thresholds in seven latin American countries. Osteoporos Int 29:707–715
pubmed: 29273826
doi: 10.1007/s00198-017-4341-4
Kanis JA, Harvey NC, Johansson H et al (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187–196
pubmed: 32043227
doi: 10.1007/s40520-019-01432-y
Shuhart CR, Yeap SS, Anderson PA, et al. (2019) Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA Cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom. 22 4 453 71
Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276
pubmed: 22434203
doi: 10.1007/s00198-012-1958-1
Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporosis Int 30:1145–1156
doi: 10.1007/s00198-019-04906-x
Ferrau F, Giovinazzo S, Messina E et al (2020) High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures. Endocrine 67:172–179
pubmed: 31376100
doi: 10.1007/s12020-019-02034-4
Xiaojuan L, Schwartz AV (2020) MRI assessment of bone marrow composition in osteoporosis. Curr Osteoporos Rep 18:57–66
doi: 10.1007/s11914-020-00562-x
Florez H, Hernández-Rodríguez J, Muxi A et al (2020) Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology 59:1574–1580
pubmed: 31628810
doi: 10.1093/rheumatology/kez464
Silva BC, Leslie WD, Resch H (2014) Trabecular bone score: a non-invasive analytical method based upon the DXA image. J Bone Min Res 29:518–530
doi: 10.1002/jbmr.2176
Yamauchi M (2009) Biochemical markers of bone turnover New aspect Biochemical bone markers of bone in patients treated with glucocorticoid. Clin Calcium 19:1092–1100
pubmed: 19638692
Burshell AL, Möricke R, Correa-Rotter R et al (2010) Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:935–939
pubmed: 20060081
doi: 10.1016/j.bone.2009.12.032
Jacobsson M, van Raalte DH, Heijboer AC et al (2020) Short-term glucocorticoid treatment reduces circulating sclerostin concentrations in healthy young men: a randomized, placebo-controlled, double-blind study. JBMR plus 4:e10341
pubmed: 32803106
pmcid: 7422706
doi: 10.1002/jbm4.10341
Briot K, Cortet B, Roux C et al (2014) Bone section of the French society for Rheumatology (SFR) and osteoporosis research information group (GRIO) Update of recommendations on the prevention and treatment of glucocorticoid- induced osteoporosis. J Bone Spine 81:493–501
doi: 10.1016/j.jbspin.2014.10.001
Weaver CM, Alexander DD, Boushey CJ et al (2020) Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the national osteoporosis foundation. Osteoporos Int 27:367–376
doi: 10.1007/s00198-015-3386-5
Homik J, Suarez-Almazor ME, Shea B et al (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis cochrane database. Syst Rev 1998:CD000952
Rizzoli R, Biver E (2015) Glucocorticoid—induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98–109
pubmed: 25385412
doi: 10.1038/nrrheum.2014.188
Rizzoli R (2021) Vitamin D supplementation: upper limit for safety revisited? Aging Clin Exp Res 33:19–24
pubmed: 32857334
doi: 10.1007/s40520-020-01678-x
Rizzoli R (2022) Dairy products and bone health. Aging Clin Exp Res 34:9–24
pubmed: 34494238
doi: 10.1007/s40520-021-01970-4
Sambrook P, Birmingham J, Kelly P et al (1993) A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752
pubmed: 7684512
doi: 10.1056/NEJM199306173282404
Yeap SS, Fauzi AR, Kong NC et al (2008) A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol 35:2344–2347
pubmed: 19004038
doi: 10.3899/jrheum.080634
Richy F, Ethgen O, Bruyere O et al (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310
pubmed: 14740153
doi: 10.1007/s00198-003-1570-5
Muir JM, Ye C, Bhandari M et al (2013) The effect of regular physical activity on bone mineral density in post-menopausal women aged 75 and over: a retrospective analysis from the Canadian multicentre osteoporosis study. BMC Musculoskelet Disord 23:253
doi: 10.1186/1471-2474-14-253
El-Khoury F, Cassou B, Latouche A et al (2015) Effectiveness of two-year balance training programme on prevention of fall induced injuries in at risk women aged 75–85 living in community: Ossébo randomised controlled trial. BMJ 22:h3830
doi: 10.1136/bmj.h3830
Madureira MM, Takayama L, Gallinaro AL et al (2007) Balance training program is highly effective in improving functional status and reducing the risk of falls in elderly women with osteoporosis: a randomized controlled trial. Osteoporos Int 18:419–425
pubmed: 17089080
doi: 10.1007/s00198-006-0252-5
de Jong Z, Munneke M, Lems WF et al (2004) Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 50:1066–1076
pubmed: 15077288
doi: 10.1002/art.20117
Zhao R, Zhang M, Zhang Q (2017) The effectiveness of combined exercise interventions for preventing postmenopausal bone loss: a systematic review and meta-analysis. J Sports Phys Ther 47:241–251
doi: 10.2519/jospt.2017.6969
Schmitt NM, Schmitt J, Dören M (2009) The role of physical activity in the prevention of osteoporosis in postmenopausal women-an update. Maturitas 63:34–38
pubmed: 19356867
doi: 10.1016/j.maturitas.2009.03.002
Chow TH, Lee BY, Ang ABF et al (2017) The effect of Chinese martial arts Tai Chi Chuan on prevention of osteoporosis: a systematic review. J Orthop Translat 26:74–84
Pongchaiyakul C, Nguyen TV, Kosulwat V et al (2004) Effects of physical activity and dietary calcium intake on bone mineral density and osteoporosis risk in a rural Thai population. Osteoporos Int 15:807–813
pubmed: 15175843
doi: 10.1007/s00198-004-1613-6
Seo S, Chun S, Newell MA et al (2015) Association between alcohol consumption and Korean young women’s bone health: a cross sectional study from the 2008 to 2011 korea national health and nutrition examination survey. BMJ Open 5:e007914
pubmed: 26463219
pmcid: 4606427
doi: 10.1136/bmjopen-2015-007914
Lopez Gavilanez E, Gavilanes AW, Chedraui P et al (2018) New FRAX-based intervention and assessment thresholds for the Ecuadorian population. Arch Osteoporos 13:1–2
doi: 10.1007/s11657-018-0521-x
Bishop N, Arundel P, Clark E et al (2014) International society of clinical densitometry fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 pediatric official positions. J Clin Densitom 17:275–280
pubmed: 24631254
doi: 10.1016/j.jocd.2014.01.004
Ward LM, Rauch F (2018) Anabolic therapy for the treatment of osteoporosis in childhood. Curr Osteoporos Rep 16:269–276
pubmed: 29589203
doi: 10.1007/s11914-018-0434-z
Cruse LM, Valeriano J, Vasey FB et al (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12:221–225
pubmed: 17023807
doi: 10.1097/01.rhu.0000242778.65766.22
Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 339:292–299
pubmed: 9682041
doi: 10.1056/NEJM199807303390502
Stoch SA, Saag KG, Greenwald M et al (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714
pubmed: 19487264
doi: 10.3899/jrheum.081207
Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a 12-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318
pubmed: 10555025
doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263
pubmed: 19362675
doi: 10.1016/S0140-6736(09)60250-6
Glüer CC, Marin F, Ringe JD et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the Euro GIOPs trial. J Bone Miner Res 28:1355–1368
pubmed: 23322362
doi: 10.1002/jbmr.1870
Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039
pubmed: 18003959
doi: 10.1056/NEJMoa071408
Hirooka Y, Nozaki Y, Okuda S et al (2021) 4-year teriparatide followed by denosumab vs continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Front Endocrinol 27:753185
doi: 10.3389/fendo.2021.753185
Curtis EM, Reginster JY, Al-Daghri N et al (2022) Management of patients at very high risk of osteoporosis fractures through sequential treatments. Aging Clin Exp Res 34:695–714
pubmed: 35332506
pmcid: 9076733
doi: 10.1007/s40520-022-02100-4
Lespessailles E, Chapurlat R (2020) High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int 31:1829–1834
pubmed: 32780152
doi: 10.1007/s00198-020-05568-w
Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis Int 31:1–12
doi: 10.1007/s00198-019-05176-3
Levy S, Fayez I, Taguchi N et al (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428–430
pubmed: 19059370
doi: 10.1016/j.bone.2008.11.001
Munns CF, Rauch F, Ward L et al (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19:1742–1745
pubmed: 15355570
doi: 10.1359/JBMR.040711
Patlas N, Golomb G, Yaffe P (1999) Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60:68–73
pubmed: 10440778
doi: 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H
Chan B, Zacharin M (2006) Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91:2017–2020
pubmed: 16551739
doi: 10.1210/jc.2005-2548
Minsker DH, Manson JM, Peter CP (1993) Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121:217–223
pubmed: 8346538
doi: 10.1006/taap.1993.1148
Kanis JA, Johansson H, Harvey NC et al (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32:1951–1960
pubmed: 33813622
doi: 10.1007/s00198-021-05942-2
Sandru F, Carsote M, Dumitrascu MC et al (2020) Glucocorticoid and trabecular bone score. J Med Life 13:449–453
pubmed: 33456590
pmcid: 7803323
doi: 10.25122/jml-2019-0131
Brunova J, Kratochvilova S, Stepankova J (2018) Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol 9:162
doi: 10.3389/fendo.2018.00162
Kageyama G, Okano T, Yamamoto Y et al (2016) Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: a retrospective study. Bone Rep 17:3–8
McCloskey EV, Chotiyarnwong P, Harvey NC et al (2022) Population screening for fracture risk in postmenopausal women—a logical step in reducing the osteoporotic fracture burden? Osteoporos Int. https://doi.org/10.1007/s00198-022-06419-6
doi: 10.1007/s00198-022-06419-6
pubmed: 36282342
pmcid: 9568435
Green SB, Pappas AL (2014) Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm 71:2029–2036
pubmed: 25404594
doi: 10.2146/ajhp140041
Yarrington JT, Capen CC, Black HE et al (1976) Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion. Am J Pathol 83:569–588
pubmed: 180813
pmcid: 2032513
French AE, Kaplan N, Lishner M et al (2003) Taking bisphosphonates during pregnancy. Can Fam Physician 49:1281–1282
pubmed: 14594094
pmcid: 2214129
Stathopoulos IP, Liakou CG, Katsalira A et al (2011) The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 10:280–291
doi: 10.14310/horm.2002.1319
Saag KG, Wagman RB, Geusens P et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454
pubmed: 29631782
doi: 10.1016/S2213-8587(18)30075-5
Saag KG, Pannacciulli N, Geusens P et al (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind. Double-Dummy Trial Arthritis Rheumatol 71:1174–1184
pubmed: 30816640
doi: 10.1002/art.40874
Al Adhoubi NK, Al Salmi I (2021) Safety of denosumab in patients with chronic kidney disease. Saudi J Kidney Dis Transpl 32:1235
pubmed: 35532692
Scanlon PD, Connett JE, Wise RA et al (2004) Loss of bone density with inhaled triamcinolone in lung health study II. Am J Respir Crit Care Med 170:1302–1309
pubmed: 15374846
doi: 10.1164/rccm.200310-1349OC
Bianchi ML, Leonard MB, Bechtold S et al (2014) International society for clinical densitometry bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD pediatric official positions. J Clin Densitom 17:281–294
pubmed: 24656723
doi: 10.1016/j.jocd.2014.01.005